Izelvay Astellas Pharma Europe B.V. · Application withdrawn · ATC S01XA32
Therapeutic indication (EMA)
Indicated for the treatment of adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Active substance
Avacincaptad pegol
- US FDA 1
- EMA 1
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| IZERVAY | EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) | solution · intravitreal | ASTELLAS | Prescription | 4 Aug 2023 |
EMA European Union — centrally authorised medicines
Safety signals and safety-related labeling changes
- US FDA 27 Feb 2026 IZERVAY — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.